Search
for
Sort by
Research 31–60 of 1000+
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
- Efficacy of tofacitinib in pediatric alopecia universalis
- Alopecia universalis successfully treated with tofacitinib
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
- Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Treatment of Lichen Planopilaris With Abrocitinib
- Upadacitinib for Alopecia: Current Evidence and Clinical Insights